Medivir AB appoints Pia Baumann as chief medical officer
Pharmaceutical company Medivir AB has announced that Pia Baumann has taken the role of chief medical officer. Medivir focuses on the development of innovative cancer treatments in areas of high unmet medical need.
Pia Baumann now takes a role on Medivir’s management team, meaning her responsibilities include the continued clinical development of the candidate drug fostroxacitabine bralpamide (fostrox).
Baumann earned her PhD at the Karolinska Institute and has extensive experience in the drug development sphere, specifically within the cancer field. She has experience of clinical work at Karolinska Hospital as well as having experience at both large pharmaceutical companies and smaller biotech companies.
Recently, Baumann has worked at AstraZeneca as vice president medical with global responsibility for the company’s Tagrisso and Lung Cancer franchise. Prior to this she worked at Takeda, Incyte and ARIAD Pharmaceuticals holding various leading global positions.
Jens Lindberg, chief executive officer at Medivir AB, commented: “I am very pleased that Pia now has taken up the role as chief medical officer. She is joining us at an exciting time, considering we have just communicated that fostrox is now entering the expansion phase (phase 2a) in combination with Lenvima. Her experience in global drug development as well as interaction and cooperation with regulatory authorities will be very important for the continued clinical development of fostrox.”